Regeneron records mixed results for Q1 as Eylea revenues fall
[ad_1] Tarrytown-based Regeneron Pharmaceuticals reported mixed results in the first quarter of 2024, according to financials released Thursday, as sales of its leading eye disease...
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More
